Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cassava Sciences Inc (NQ: SAVA )

3.840 -0.140 (-3.52%)
Streaming Delayed Price Updated: 1:00 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cassava Sciences Inc

< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
33 34 Next >
Stay Far Away From Cassava Sciences Amid Data Integrity Criticisms
Serious allegations have been made against Cassava by multiple sources, making SAVA stock far too risky for investors at this point. 
Via InvestorPlace
Take Full Advantage of Weakness in Cassava Sciences Stock
Cassava could run back to $40 again. Should the company get a positive nod for its Alzheimer’s treatment, it could see $140 again. 
Via InvestorPlace
Cassava Sciences Is a Worthwhile Bet to Consider
FDA approval for Simufilam and successful trials of a new blood test to detect Alzheimer's disease could help propel SAVA stock back up. 
Via InvestorPlace
CASSAVA ALERT: Bragar Eagel & Squire, P.C. is Investigating Cassava Sciences, Inc. on Behalf of Cassava Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
The Crowd Has Wisely Soured on Cassava Sciences Stock
Recent headlines suggest Simulfilam has a slim chance of obtaining FDA approval, justifying the move of SAVA stock to lower prices. 
Via InvestorPlace
Why Is Cassava Sciences (SAVA) Stock Down Today?
SAVA stock is tumbling after The New York Times reported that multiple experts are skeptical about Cassava's data and its main theory. 
Via InvestorPlace
54 Biggest Movers From Yesterday
Gainers Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) shares jumped 325.9% to close at $10.35 on Tuesday after Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced a deal to... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Checkmate Pharmaceuticals (NASDAQ:CMPI) stock increased by 331.9% to $10.41 during Tuesday's regular session. Trading volume for Checkmate Pharmaceuticals'... 
Via Benzinga
$1000 Invested In Cassava Sciences 5 Years Ago Would Be Worth This Much
Cassava Sciences (NASDAQ:SAVA) has outperformed the market over the past 5 years by 19.11% on an annualized basis producing an average annual return of 32.41%. Currently, Cassava Sciences has a market... 
Via Benzinga
38 Stocks Moving In Tuesday's Mid-Day Session
Gainers Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) climbed 329.2% to $10.43 after Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced a deal to acquire the company for $... 
Via Benzinga
Why Is ToughBuilt Industries (TBLT) Stock Up 65% Today?
ToughBuilt Industries (TBLT) stock is rocketing higher Tuesday following the release of the company's Q4 2021 earnings report. 
Via InvestorPlace
Why Is Johnson & Johnson (JNJ) Stock in Focus Today?
Johnson & Johnson (JNJ) stock is on the move Tuesday as investors react to the company's earnings report for the first quarter of 2022. 
Via InvestorPlace
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 242 companies hit new 52-week lows. Noteworthy Mentions In Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week low was... 
Via Benzinga
New York Times Report Fresh Allegations On Cassava's Simufilam Alzheimer's Trials, Shares Fall
Cassava Sciences Inc (NASDAQ: SAVA) shares are shedding over 20% after 
Via Benzinga
Benzinga's Daily Brief On Trending Tickers For April 19, 2022: Plug Power, Twitter, Cassava Sciences And More
Benzinga’s “Daily Brief On Trending Tickers” features top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news items... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Checkmate Pharmaceuticals (NASDAQ:CMPI) shares increased by 331.5% to $10.4 during Tuesday's pre-market session. The market value of their outstanding shares... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning! It's time to start off another busy day of trading with a dive into the biggest pre-market stock movers for Tuesday! 
Via InvestorPlace
23 Stocks Moving in Tuesday's Pre-Market Session
Gainers ToughBuilt Industries, Inc. (NASDAQ: TBLT) rose 44.9% to $0.2125 in pre-market trading as the company posted a narrower FY21 loss. Sharps Technology, Inc. (NASDAQ: STSS... 
Via Benzinga
How Is The Market Feeling About Cassava Sciences Inc?
Cassava Sciences Inc's (NASDAQ:SAVA) short percent of float has fallen 3.25% since its last report. The company recently reported that it has 10.93 million shares sold short,... 
Via Benzinga
Cassava Sciences Is Worth Considering After Hitting Its Latest Trough
The company has no debt and is cash rich. If it receives FDA approval for its Simufilam drug, the SAVA stock price will catapult. 
Via InvestorPlace
51 Biggest Movers From Yesterday
Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM) shares surged 148.2% to close at $5.61 on Tuesday after the company announced that two of its designed mRNA molecules are... 
Via Benzinga
Dear SOFI Stock Fans, Mark Your Calendars for May 1
SoFi Technologies (SOFI) stock is slipping on Tuesday and may see further falls this week ahead of student loan moratorium news. 
Via InvestorPlace
This Is What Whales Are Betting On Cassava Sciences
A whale with a lot of money to spend has taken a noticeably bullish stance on Cassava Sciences. Looking at options history for Cassava Sciences (NASDAQ:SAVA) we detected 14 strange trades. 
Via Benzinga
Why Is Cassava Sciences (SAVA) Stock Down Today?
Cassava Sciences (SAVA) stock is falling on Tuesday as investors react to a recent fireside chat held by CEO Remi Barbier. 
Via InvestorPlace
Here's How Much You Would Have Made Owning Cassava Sciences Stock In The Last 5 Years
Cassava Sciences (NASDAQ:SAVA) has outperformed the market over the past 5 years by 29.74% on an annualized basis producing an average annual return of 43.85%. Currently, Cassava Sciences has a market... 
Via Benzinga
R&D Efforts for Alzheimer’s Therapies on the Rise with over 120 Drugs in Development
Palm Beach, FL – March 31, 2022 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is an irreversible, progressive neurodegenerative disease. It is the most common cause of dementia... 
Via FinancialNewsMedia
Risk-on Biotech Investors Should Buy Cassava Sciences
SAVA stock is volatile but worthwhile after opinion shifts in its favor. Remember, it has a blockbuster Alzheimer's drug nearing launch. 
Via InvestorPlace
Here's How Much $100 Invested In Cassava Sciences 5 Years Ago Would Be Worth Today
Cassava Sciences (NASDAQ:SAVA) has outperformed the market over the past 5 years by 26.48% on an annualized basis. Buying $100 In SAVA: 5 years ago, an investor could have... 
Via Benzinga
Keep Risk in Mind With Cassava Sciences Stock, but Don’t Dismiss Upside Potential
A recent admission by management underscores the need to make SAVA stock, at best, a small, speculative position in your portfolio. 
Via InvestorPlace
Cassava Sciences Is in a Bleak Midwinter Waiting for Spring and Better Days
SAVA stock is driven by updates on clinical Phase 3 trials and lots of irrationality. Meanwhile, an FDA approval may take quite some time. 
Via InvestorPlace
< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
33 34 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.